Platform for the interdisciplinary study of cardiovascular, metabolic and neurovascular diseases (PICMAN) protocol

• Main Authors: Dalakoti, Mayank, Leow, Melvin Khee Shing, Khoo, Chin Meng, Yang, Hayang, Ling, Lieng Hsi, Muthiah, Mark, Tan, Eunice, Lee, Jonathan, Dan, Yock Young, Chew, Nicholas, Seow, Wei Qiang, Soong, Poh Loong, Gan, Louis, Gurung, Rijan, Ackers-Johnson, Matthew, Hou, Han Wei, Sachaphibulkij, Karishma, MacAry, Paul, Low, Gwen, Ang, Christy, Yeo, Tee Joo, Djohan, Andie Hartanto, Li, Tony, Yeung, Wesley, Soh, Rodney, Sia, Ching Hui, Panday, Vinay, Loong, Shaun S. E., Tan, Benjamin Y. Q., Yeo, Leonard L. L., Teo, Lynette, Chow, Pierce, Foo, Roger
• Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
• Format: Article
• Language: English
• Published: 2024
• Subjects: Medicine, Health and Life Sciences; Cardiovascular disease; Cerebral atherosclerosis
• Online Access: https://hdl.handle.net/10356/173857
• Institution: Nanyang Technological University

Through extensive multisystem phenotyping, the central aim of Project PICMAN is to correlate metabolic flexibility to measures of cardiometabolic health, including myocardial diastolic dysfunction, coronary and cerebral atherosclerosis, body fat distribution and severity of non-alcoholic fatty liver disease. This cohort will form the basis of larger interventional trials targeting metabolic inflexibility in the prevention of cardiovascular disease. Participants aged 21-72 years with no prior manifest atherosclerotic cardiovascular disease (ASCVD) are being recruited from a preventive cardiology clinic and an existing cohort of non-alcoholic fatty liver disease (NAFLD) in an academic medical centre. A total of 120 patients will be recruited in the pilot phase of this study and followed up for 5 years. Those with 10-year ASCVD risk ≥ 5% as per the QRISK3 calculator are eligible. Those with established diabetes mellitus are excluded. Participants recruited undergo a detailed assessment of health behaviours and physical measurements. Participants also undergo a series of multimodality clinical phenotyping comprising cardiac tests, vascular assessments, metabolic tests, liver and neurovascular testing. Blood samples are also being collected and banked for plasma biomarkers, 'multi-omics analyses' and for generation of induced pluripotent stem cells (iPSC). Extensive evidence points to metabolic dysregulation as an early precursor of cardiovascular disease, particularly in Asia. We hypothesise that quantifiable metabolic inflexibility may be representative of an individual in his/her silent, but high-risk progression towards insulin resistance, diabetes and cardiovascular disease. The platform for interdisciplinary cardiovascular-metabolic-neurovascular diseases (PICMAN) is a pilot, prospective, multi-ethnic cohort study.